Why We Keep Getting Testosterone Wrong And What It’s Costing Our Patients

A clinical commentary for providers in women’s health

I want to start with a number.

It takes an average of 12 years for new evidence to make its way into standard clinical practice. Twelve years. In medicine, that gap has a cost and in women’s health, testosterone is one of the clearest examples of where we’re still paying it.

The State of Play

ISSWSH(The International Society for the Study of Women’s Sexual Health) published their process of care document on testosterone use in women years ago. The evidence supporting testosterone therapy for HSDD in postmenopausal women is not new. The safety profile at physiologic doses without increased cardiovascular or breast cancer risk has been replicated across multiple studies.

And yet: no FDA-approved testosterone product for women exists in the United States. Prescribing remains off-label and compounding quality is inconsistent. Clinical education is sparse. Most NPs, PAs, and MDs who didn’t subspecialize in women’s health have received minimal to no formal training in this area.

The result? Patients with low testosterone and a symptomatic presentation fatigue, low libido, mood changes, cognitive fog who sit in exam rooms and hear “your labs look fine” or “that’s just part of menopause.”

We can do better.

The Clinical Confidence Gap

I’ve spoken with providers across the country through The Q-Spot, and the testosterone hesitation is remarkably consistent. The common threads:

• “I don’t know what dose to use.”

• “I’m worried about side effects.”

• “I’m not sure how to explain this to patients.”

• “I don’t feel like I have the foundation to do this confidently.”

This isn’t about clinical inadequacy. It’s about a gap in training that was created by the system not by the providers working within it. Women’s health has historically been under-researched, under-funded, and under-taught. Testosterone in women is a perfect microcosm of that larger failure.

What Confident Practice Looks Like

Here’s what I know from years of integrating testosterone therapy into my practice: the assessment is learnable, the prescribing is learnable, the monitoring is learnable, the patient communication is learnable. None of it requires a fellowship it requires focused, evidence-based education and a willingness to sit with the nuance.

When I watch providers who’ve completed our Midlife 101 course come back and describe their first testosterone conversation, or their first patient who cried with relief at finally having an answer that is what clinical education is supposed to do. That is what changes outcomes.

The Practice Business Case (Because It Matters Too)

Testosterone therapy is one of the areas where integrative women’s health practices are clearly differentiating themselves. Patients are increasingly informed they’ve heard about testosterone on podcasts, in the news, in their group chats. They’re coming in asking for it. Clinicians who have the clinical confidence to address it well are building reputations as the go-to practice for comprehensive hormonal care in their communities.

If you’re building a private practice or expanding your service offerings, this is one of the highest-leverage clinical skill sets you can develop. The demand is there. The evidence is there. The gap is training.

A Call to Action for Our Community

We cannot close the gap between evidence and practice if we don’t first close the education gap.

If you’re a clinician in women’s health who wants to do this well The Q-Spot’s Midlife 101 course covers testosterone therapy in depth, alongside the full midlife clinical landscape: menopause, metabolic health, sexual medicine, thyroid, and the business side of building a modern women’s health practice that actually serves your patients.

12 CE hours. Evidence-based. Practical. Built by a clinician who has been in the trenches for over two decades.

www.theqspot.net, Midlife 101 available now at a limited-time price.

Your patients are waiting.